It has recently been emphasised that a subset of patients with type 2 Gaucher disease die in the neonatal period. This report describes an Afghani family with two conceptuses having severe, prenatally detected Gaucher disease. Mutational analysis showed that the family carried a known complex allele which included mutations at amino acids L444P, A456P, and V460V. Although glucocerebrosidase RNA was present, an affected fetus had virtually no glucocerebrosidase cross reactive material on western analyses. The severe clinical course and pathology observed in these patients resemble that of the null allele Gaucher mouse, and suggest that the absence of glucocerebrosidase activity results in early death. (J Med Genet 1996;33:132-136) 
Until recently type 2 (acute neuronopathic) Gaucher disease was considered stereotypic in presentation, with neurological deterioration and death by the age of 2 to 3 years.' However, the generation of a null allele, knock-out Gaucher mouse23 led to increased recognition of type 2 patients with a much more aggressive phenotype, who die as neonates. Although 22 neonates with type 2 Gaucher disease have been reported to our knowledge, including some who presented with hydrops fetalis or congenital ichthyosis,'24' there has not been comprehensive analysis of glucocerebrosidase mutations, mRNA, and protein in these patients.
In this report we describe the molecular characterisation of a family in which two conceptuses had severe, prenatally detected Gaucher disease.
Case reports
Although consanguinity cannot be proven, the proband's parents both come from the same small, isolated, and inbred Afghani population.
They had one healthy son. The second pregnancy (case 1) was complicated by hydramnios developing between 27 and 30 weeks of pregnancy. Prenatal ultrasound detected severe hydrops fetalis with bilateral hydrothorax and fetal hypokinesia with multiple joint contractures. Since fetal blood sampling indicated thrombocytopenia and abnormal liver enzymes, labour was induced at 33 weeks' gestation. A 1970 g male child (fig 1) measuring 40 cm in length was delivered by caesarean section. He exhibited joint contractures, hepatosplenomegaly, pulmonary hypoplasia, muscular atrophy, and dysmorphic features that included a flattened nose with small nares and malformed ears. The skin appeared tight and shiny, especially over the face, neck, ears, thorax, and extremities. The infant died in the first hour of life. The diagnosis of type 2 Gaucher disease was based on the presence of Gaucher cells in many organs from necropsy material. The parents were subsequently confirmed by enzyme analysis to be heterozygotes for Gaucher disease (mother had 62 1% and father had 66 7% of control glucocerebrosidase activity). During a third pregnancy (case 2), the prenatal diagnosis of Gaucher disease was made by enzyme assay on cultured amniocytes obtained at week 15. Neither hydrops nor joint contractures was found in the 640 g, 30 cm male fetus which was aborted at 23 weeks' gestation. Genomic DNA was prepared from cultured cell lines from patients and controls as previously described.6 Human genomic DNA was digested with BamHI, electrophoresed on a 1% agarose gel, transferred to supported nitrocellulose membranes (Schleicher & Schuell, Keene NH), ultraviolet light cross linked, and then hybridised to a glucocerebrosidase cDNA probe as previously described.7 Genomic DNA was also digested with SstII and electrophoresed on a 0-6% I.D.NATM agarose gel (FMC Rockland ME), transferred, and hybridised as described above.
RNA PREPARATION AND NORTHERN BLOT HYBRIDISATION
Total RNA was isolated from frozen cell pellets from case 2 and controls using RNAzol`B (Biotecx Houston, TX). Approximately 17 ptg of total RNA from each sample was electrophoresed on a 1% agarose formaldehyde gel, transferred to a supported nitrocellulose membrane, and ultraviolet light cross linked. The membrane was prehybridised using 33 ztl/cm2 blot of Quik hybridisation solution (Stratagene, Lajolla, CA) at 680C for 20 minutes, and then hybridised at 680C for one hour using a 32p dCTP random labelled full length glucocerebrosidase cDNA probe.7 The blot was washed twice in a 2 x SSC/0 1% (W/V) SDS at room temperature for 15 minutes and once with 0 1 x SSC/0 1% (W/V) SDS at 60°C for 30 minutes. The membrane was exposed to Kodak XAR film with an intensifying screen at -800C overnight.
MUTATION ANALYSIS
Screening for the N370S, L444P, R463C, and 84insG mutations was performed as previously described.8 A 1290 bp genomic glucocerebrosidase segment, spanning exons 9 to 11, was selectively amplified using oligonucleotide primers that did not amplify the pseudogene region (forward primer 5'-AACATGAT-TCCCTATCTTC-3 from intron 8, reverse primer 5'ACCACCTAGAGGGGAAAGTG-3' from untranslated exon 1 1).8 This amplified DNA fragment was isolated with GeneClean II (Bio 101 LaJolla, CA) and cycle sequencing was performed according to the Taq di deoxyT' terminator kit (Applied Biosystems, Porter City, IA). The PCR product was purified using an AQUA Select-D-50 column (5' Prime, 3' Prime, Boulder, CO), vacuum dried, resuspended in loading buffer, denatured at 90°C, and loaded on a 4-75% acrylamide, 8 3 mol/l urea and 1 x TBE gel. Results were analysed using the 373 DNA Sequencing Analysis software package (Applied Biosystem, Porter City, IA).
Forward oligonucleotide primers for sequencing were 59F 5'-CACAGGGCTGA-CCTACCCA-3' (located in intron 8); 142F 5'-GCAGGAGTTATGGGGTGGGTC-3' (located in intron 9); 878F 5'-GTGGGCTGAA-GACAGCGTTGG-3' (located in intron 10).
PROTEIN STUDIES
Cell extracts were prepared from frozen human cell pellets and from mouse tissue or fibroblasts as previously described.3 Glucocerebrosidase activity was measured using 4-methylumbelliferyl-,B-D-glucopyranoside as substrate.9 Nine micrograms of protein from each sample were electrophoresed on denaturing 12% polyacrylamide gels, and the separated proteins were transferred to Immobilon P membranes. The membranes were incubated I.. 2 Gaucher disease.
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